Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Julphar
Medtronic
Daiichi Sankyo
Colorcon
Federal Trade Commission
Farmers Insurance
Teva
Healthtrust

Generated: October 15, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,801,925

« Back to Dashboard

Title:Potentiation of glucose elimination
Abstract: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin in diabetics requiring basal insulin replacement are provided.
Inventor(s): Boss; Anders Hasager (Princeton, NJ), Steiner; Solomon S. (Mount Kisco, NY), Woods; Rodney J. (New Hampton, NY), Sulner; Joseph W. (Paramus, NJ)
Assignee: MannKind Corporation (Westlake Village, CA)
Filing Date:Mar 05, 2015
Application Number:14/639,860
Claims:1. A method of restoring normal insulin kinetics in a patient in need thereof comprising administering to a patient having an insulin-related disorder an inhaled insulin composition comprising a diketopiperazine such that said inhaled insulin composition produces in the patient a rapid increase in serum insulin concentration of between about 75 mU/L and about 375 mU/L within 20 minutes of administration, wherein said patient's glucose elimination rate returns to baseline by about 6 hours after administration.

2. The method of claim 1, wherein said rapid increase in serum insulin concentration is between about 100 mU/L and about 375 mU/L.

3. The method of claim 2, wherein said rapid increase in serum insulin concentration is between about 125 mU/L and about 375 mU/L.

4. The method of claim 1, wherein said rapid increase in serum insulin concentration is achieved within about 15 minutes after administration.

5. The method of claim 1, wherein said rapid increase in serum insulin concentration descends through half maximal within about 80 minutes after administration.

6. The method of claim 1, wherein said rapid increase in serum insulin concentration descends through half maximal within about 50 minutes after administration.

7. The method of claim 1, wherein said rapid increase in serum insulin concentration descends through half maximal within about 35 minutes after administration.

8. The method of claim 1, wherein said patient's glucose elimination rate reaches its maximum between about 30 and about 90 minutes after administration.

9. The method of claim 8, wherein said patient's glucose elimination rate reaches its maximum between about 45 and about 60 minutes after administration.

10. The method of claim 1, wherein said diketopiperazine is fumaryl diketopiperazine.

11. The method of claim 1, wherein said inhaled insulin composition is administered from approximately 10 minutes prior to a meal to approximately 30 minutes after a meal.

12. The method of claim 11 wherein about 74% of the glucose lowering activity of said inhaled insulin composition has been expended within about 180 minutes after administration.

13. The method of claim 12 wherein said patient's glucose elimination rate returns to baseline within about 270 minutes after administration.

14. A method of restoring normal insulin kinetics in a patient in need thereof wherein said comprising administering to a patient having an insulin-related disorder from approximately 10 minutes prior to a meal to approximately 30 minutes after a meal an inhaled insulin composition comprising fumaryl diketopiperazine; wherein said composition produces in the patient a a rapid increase in serum insulin levels of at least between about 75 mU/L and about 375 mU/L achieved within about 20 minutes after administration; and wherein about 74% of the glucose lowering activity of said inhaled insulin composition has been expended within about 180 minutes after administration, and said patient's glucose elimination rate returns to baseline within about 270 minutes after administration.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Julphar
AstraZeneca
Chinese Patent Office
Chubb
Johnson and Johnson
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.